MedTrace Logo

Second eFramngham Heart Study

NCT04752657 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 492

Last updated 2025-03-19

Study results available
· View outcomes & findings →

Summary

In the electronic Framingham Heart Study (eFHS), the investigators developed and deployed a mobile app to collect cardiovascular risk factors and event data and test them against cardiovascular data collected in the Framingham research clinic for the FHS.

Participants enrolled in eFHS receive a series of digital surveys modules to complete on a regularly occurring schedule. The objective of the planned randomized trial is to test the effect of administering half of survey modules every 2 weeks versus all survey modules every 4 weeks on improving participants' response rates.

There will be 4 survey periods. Period 1 encompasses all survey modules administered from baseline up to week 8 (19 surveys/tasks per participant); period 2 from week 8 up to week 16 (18 surveys/tasks per participant); period 3 from week 16 up to week 24; period 4 from week 24 (16 surveys/tasks per participant).

Conditions

Interventions

OTHER

Delayed administration of survey modules

The intervention consists in delaying the administration of the physical function, physical activity, and events survey modules by 2 weeks

OTHER

Regular administration of survey modules

The physical function, physical activity, and events survey modules are administered according to the regular pattern

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Boston University

    lead OTHER

Principal Investigators

  • Joanne Murabito · Framingham Heart Study

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-21
Primary Completion
2023-12-28
Completion
2023-12-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04752657 on ClinicalTrials.gov